Vertex Pharmaceuticals Incorporated (VRTX) Stock Price & Analysis
Market: NASDAQ • Sector: Healthcare • Industry: Biotechnology
Vertex Pharmaceuticals Incorporated (VRTX) Profile & Business Summary
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Key Information
| Ticker | VRTX |
|---|---|
| Exchange | NASDAQ |
| Official Site | https://www.vrtx.com |
Market Trend Overview for VRTX
One model, two time views: what the market looks like right now, and where the larger trend is heading over time.
SRE (WhaleQuant Structural Regime Engine) SRE evaluates how price structure evolves across daily and weekly timeframes to define the prevailing market regime. Beyond identifying trends, consolidations, and exhaustion phases, it distinguishes between raw structural strength and deployable participation quality. The model dynamically adjusts for structural context and extension risk, assessing whether conditions are supportive, stretched, fragile, or structurally impaired. Its purpose is not to forecast precise price levels, but to determine whether risk deployment is aligned with underlying market structure.
Longer-Term Market Trend (Mid to Long Term)
Shows the bigger market trend, how strong it is, and where risks may start to build over the next few weeks or months. — Updated as of 2026-10-01 (ET)
As of 2026-10-01, VRTX is showing signs of slowing down. Over the longer term, the trend remains bullish.
VRTX last closed at 506.74. The price is about 1.0 ATR below its recent average price (518.43), and the market is currently in a trend that may be losing strength. Price at 506.74 is near minor support around 502.29. Momentum may slow, while minor resistance sits near 525.29. View Support & Resistance from Options
The broader uptrend is still intact, but price has moved far from its recent average, increasing the risk of a pullback.
Trend score: 55 out of 100. Overall alignment is unclear. The market is currently in a late-stage trend that may be losing strength. The longer-term trend is still positive, but short-term signals are not yet confirming it.
A key downside risk boundary is near 501.23. If price falls below this area, the current structure would likely weaken further.
On 2026-09-09, trend conditions deteriorated, suggesting that moves in the prior direction became less dependable.
[2026-08-27] Price moved quickly and looked strong, but participation was limited.
Recent price action continues to trend lower in a relatively orderly manner, with no clear signs of structural stabilization yet emerging.
Some late-day positioning was observed, but it lacked strong overnight commitment.
The model stays neutral because the setup is not clear enough to justify a directional deployment.
The model does not issue an actionable directional forecast. Predictability is 36%, agreement is 52%, and reversal risk is 14%.
NOTE: This next-day up/down probability forecast module is still being tested for accuracy. Please do not rely on it for investment decisions. The model does not account for black swan events or company-specific fundamental news, and its estimates are based solely on technical conditions, capital flow, and market sentiment. View forecast history
This estimate uses 1-minute price, volume, and VWAP data from the last 50 trading days, with turnover-based decay. The sample period is 2026-07-23 to 2026-10-01. The current price is 506.74, 1.83% below the estimated average cost of 516.20. An estimated 29.4% of recent positioning is below the current price, while 70.4% is above it. The peak-density price is 515.80. The largest concentrated cost region is 519.50 to 531.90 and contains 25.2% of the estimated distribution. The nearest region below the current price is 486.50 to 486.70. The nearest region above the current price is 507.30 to 508.30.
Short Interest & Covering Risk for VRTX
This analysis looks at overall short interest positioning, focusing on the broader setup rather than short-term noise.
Shows how likely a short squeeze may be under current market conditions.
Short Exposure Percentile
Short interest is relatively low, indicating limited pressure from short positions. (Historical percentile: 8%)
Structure Analysis
VRTX Short positioning is starting to look crowded. Current days to cover is 5.0 trading days, meaning short positions would unwind somewhat slower than average. Short covering could add extra momentum to price moves. Price is already trending lower (20D return -9.0%). The current configuration reflects active downside pressure rather than latent structural fragility.
Risk Summary
Some early warning signs are emerging. Price strength remains intact, but underlying support may be starting to weaken.This indicator is intended as a risk filter, not a directional signal. A High or Extreme reading does not predict an immediate move, but suggests that if prices weaken, downside reactions may be more pronounced.
Why Price Reactions May Be Stronger?
Days-to-Cover is elevated versus its own history, but absolute short interest remains moderate. In the latest reporting period, short interest continues to increase. Average trading volume is weakening, indicating contracting liquidity. Phase: Building. Adaptive thresholds applied to liquidity weakness, near-high detection, and compression sensitivity. Rising short pressure is occurring while liquidity is deteriorating. As a result, similar news or market events could lead to price moves about 2× larger than usual.
Note:
Short interest data is reported every two weeks by
FINRA.
The most recent snapshot is
2026-09-15 (ET).
Because this data updates slowly, it is not intended to predict short-term price moves. Instead, it helps describe longer-term market structure and where pressure may be building if prices begin to move.